Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Transparency Directive Revisions May Accelerate Access To New Medicines, But IP Issues Set To Cause A Storm

Executive Summary

Proposed revisions to the EU Transparency Directive could drive faster access to medicines. But innovative product sponsors say IP rules will damage their business.

You may also be interested in...



Can European Efficiency Measures Boost Generics And Biosimilars? – An Interview With EGA’s Adrian van den Hoven

EGA Director General Adrian van den Hoven will call on the new European Commission and Parliament to introduce efficiency policies to increase the uptake of and access to generic drugs and biosimilars.

Pharma Hopes EU Commission Policy Report Will Lead To Real Dialogue

The European Commission's latest policy document dedicated to making the pharma industry a better global competitor advocates a new, co-operative approach, but lacks detail. The industry, though, believes the document offers hope for constructive debate in key areas.

Pharma Hopes EU Commission Policy Report Will Lead To Real Dialogue

The European Commission's latest policy document dedicated to making the pharma industry a better global competitor advocates a new, co-operative approach, but lacks detail. The industry, though, believes the document offers hope for constructive debate in key areas.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS054268

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel